Is it safe to use remdesivir in combination with a combined p-glycoprotein and CYP3A4 inhibitor?

Bahcecioglu, Omer FarukGok, SelimDurmus, Mefkure2024-08-042024-08-0420212047-99562047-9964https://doi.org/10.1136/ejhpharm-2021-002680https://hdl.handle.net/11616/99722[Abstract Not Available]eninfo:eu-repo/semantics/openAccessCOVID-19drug-related side effects and adverse reactionsdrug monitoringmetabolic side effects of drugs and substancesdrug substitutionIs it safe to use remdesivir in combination with a combined p-glycoprotein and CYP3A4 inhibitor?Letter2823347281610.1136/ejhpharm-2021-0026802-s2.0-85099747813Q2WOS:000624061900003Q3